Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3ATP2A2FXYD2
The experimentally established mechanism targets of Istaroxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 10/20 | 0.87 |
| ▸ | ATP1B1 known ✓ | P05026 | 10/20 | 0.87 |
| ▸ | ATP1A3 known ✓ | P13637 | 10/20 | 0.87 |
| ▸ | ATP1B2 known ✓ | P14415 | 10/20 | 0.87 |
| ▸ | ATP1A2 known ✓ | P50993 | 10/20 | 0.87 |
| ▸ | ATP1B3 known ✓ | P54709 | 10/20 | 0.87 |
| ▸ | FXYD2 known ✓ | P54710 | 10/20 | 0.87 |
| ▸ | ATP1A4 known ✓ | Q13733 | 10/20 | 0.87 |
| ▸ | ATP12A | P54707 | 4/20 | 0.98 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Istaroxime SCHEMBL3347161 | 1.00 | ATP12A (0.98) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL1115669 | 1.00 | ATP12A (0.98) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL1115671 | 1.00 | ATP12A (0.98) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL1115673 | 1.00 | ATP12A (0.98) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL23760714 | 0.99 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL7298591 | 0.99 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL5053480 | 0.99 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL22116205 | 0.99 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL8450412 | 0.99 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL1427271 | 0.99 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087374-A1 | Methods for Treatment and Diagnosis of Pulmonary Diseases Based on the Expression of SERCA2 Protein | NATIONAL JEWISH HEALTH | 2010-04-08 | — | — | US | claimed |
| WO-2010040130-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF PULMONARY DISEASES BASED ON THE EXPRESSION OF SERCA2 PROTEIN | NATIONAL JEWISH HEALTH (US) | 2010-04-08 | — | — | WO | claimed |
| US-20240293426-A1 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | WINDTREE THERAPEUTICS, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2022159678-A9 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | WINDTREE THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022159678-A1 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | WINDTREE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20100087374-A1 | Methods for Treatment and Diagnosis of Pulmonary Diseases Based on the Expression of SERCA2 Protein | NATIONAL JEWISH HEALTH | 2010-04-08 | — | — | US | disclosed |
| WO-2010040130-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF PULMONARY DISEASES BASED ON THE EXPRESSION OF SERCA2 PROTEIN | NATIONAL JEWISH HEALTH (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293426-A1 | INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE | TNNI3, TNNT2, TNNC1 | ATP1A1 3174/4885ATP1B1 3732/4885ATP1A3 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.